Avadel Pharmaceuticals plc

NASDAQ:AVDL

17.33

-0.05 (-0.29%)

5:34:13 PM EDT: $17.33 0.00 (0.00%)

Market Cap (Intraday)	1.65B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	22.22

See more stats

Estimates Current Quarter

Revenue	$26.66 Million
Adjusted EPS	-$0.23

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Avadel Pharmaceuticals plc Stock, NASDAQ:AVDL

10 Earlsfort Terrace, Block 10-1, 2nd Floor, Dublin, Dublin 02

Ireland

Phone: +353.1.901.5201

Number of Employees: 154

http://www.avadel.com

Description

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment ofÃ?Â cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.